(b).
Measures | SAT II scores | |||
---|---|---|---|---|
Pain improvement | Impact summary | Treatment continuation | Treatment comparison | |
BPI-DN item 5 | −0.54∗∗∗ | −0.42∗∗∗ | −0.29∗∗∗ | −0.39∗∗∗ |
BPI-DN item 5 change from baseline | −0.58∗∗∗ | −0.52∗∗∗ | −0.42∗∗∗ | −0.47∗∗∗ |
| ||||
BPI-DN item 9F | −0.42∗∗∗ | −0.31∗∗∗ | −0.21∗∗ | −0.35∗∗∗ |
BPI-DN item 9F change from baseline | −0.53∗∗∗ | −0.49∗∗∗ | −0.36∗∗∗ | −0.47∗∗∗ |
| ||||
HADS anxiety subscale | −0.10 | −0.06 | −0.08 | −0.12∗ |
HADS anxiety subscale change from baseline | −0.06 | −0.10 | −0.04 | −0.06 |
HADS depression subscale | −0.09 | −0.09 | −0.09 | −0.11 |
HADS depression subscale change from baseline | −0.12∗ | −0.18∗∗ | −0.13∗ | −0.14∗ |
PGIC | −0.77∗∗∗ | −0.74∗∗∗ | −0.57∗∗∗ | −0.74∗∗∗ |
EQ-5D index | 0.30∗∗∗ | 0.28∗∗∗ | 0.18∗ | 0.23∗∗∗ |
EQ-5D index change from baseline | 0.27∗∗∗ | 0.30∗∗∗ | 0.27∗∗∗ | 0.24∗∗∗ |
EQ-5D VAS | 0.23∗∗∗ | 0.24∗∗∗ | 0.20∗∗ | 0.25∗∗∗ |
EQ-5D VAS change from baseline | 0.20∗∗ | 0.23∗∗∗ | 0.21∗∗ | 0.22∗∗∗ |
1Spearman's rank order correlation. ∗p < 0.05; ∗∗p < 0.001; ∗∗∗p < 0.0001.